Access the full text.
Sign up today, get DeepDyve free for 14 days.
(Proietti M, Lip GY. Simple decision-making between a vitamin K antagonist and non-vitamin K antagonist oral anticoagulant: using the SAMe-TT2R2 score. Eur Heart J Cardiovasc Pharmacother 2015;1:150–2.)
Proietti M, Lip GY. Simple decision-making between a vitamin K antagonist and non-vitamin K antagonist oral anticoagulant: using the SAMe-TT2R2 score. Eur Heart J Cardiovasc Pharmacother 2015;1:150–2.Proietti M, Lip GY. Simple decision-making between a vitamin K antagonist and non-vitamin K antagonist oral anticoagulant: using the SAMe-TT2R2 score. Eur Heart J Cardiovasc Pharmacother 2015;1:150–2., Proietti M, Lip GY. Simple decision-making between a vitamin K antagonist and non-vitamin K antagonist oral anticoagulant: using the SAMe-TT2R2 score. Eur Heart J Cardiovasc Pharmacother 2015;1:150–2.
(2011)
Apixaban versus warfarin in patients with atrial fibrillationN Engl J Med, 365
J. Hsu, M. Akao, M. Abe, Karen Anderson, Á. Avezum, N. Glusenkamp, S. Kohsaka, D. Lane, G. Lip, Changsheng Ma, F. Masoudi, T. Potpara, T. Siong, M. Turakhia, H. Tse, J. Rumsfeld, T. Maddox (2016)
International Collaborative Partnership for the Study of Atrial Fibrillation (INTERAF): Rationale, Design, and Initial DescriptivesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 5
V. Sjögren, B. Grzymala-Lubanski, H. Renlund, L. Friberg, G. Lip, P. Svensson, A. Själander (2015)
Safety and efficacy of well managed warfarinThrombosis and Haemostasis, 113
(2016)
Stroke prevention in atrial fibrillationLancet, 388
(2012)
2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm AssociationEur Heart J, 33
P. Kirchhof, S. Benussi, D. Kotecha, A. Ahlsson, D. Atar, B. Casadei, M. Castellà, H. Diener, H. Heidbuchel, J. Hendriks, G. Hindricks, A. Manolis, J. Oldgren, B. Popescu, U. Schotten, B. putte, P. Vardas (2016)
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.European heart journal, 37 38
P. Kirchhof, B. Ammentorp, H. Darius, R. Caterina, J. Heuzey, R. Schilling, J. Schmitt, J. Zamorano (2013)
Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events—European Registry in Atrial Fibrillation (PREFER in AF)Europace, 16
P. Kirchhof, S. Benussi, D. Kotecha, A. Ahlsson, D. Atar, B. Casadei, M. Castellà, H. Diener, H. Heidbuchel, J. Hendriks, G. Hindricks, A. Manolis, J. Oldgren, B. Popescu, U. Schotten, B. putte, P. Vardas, S. Agewall, J. Camm, G. Esquivias, W. Budts, S. Carerj, F. Casselman, A. Coca, R. Caterina, S. Deftereos, D. Dobrev, J. Ferro, G. Filippatos, D. Fitzsimons, B. Gorenek, M. Guenoun, S. Hohnloser, P. Kolh, G. Lip, A. Manolis, J. McMurray, P. Ponikowski, R. Rosenhek, F. Ruschitzka, I. Savelieva, Sanjay Sharma, P. Suwalski, J. Tamargo, C. Taylor, I. Gelder, A. Voors, S. Windecker, J. Zamorano, K. Zeppenfeld (2016)
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 18 11
R. Caterina, S. Husted, L. Wallentin, F. Andreotti, H. Arnesen, F. Bachmann, C. Baigent, K. Huber, J. Jespersen, S. Kristensen, G. Lip, J. Morais, L. Rasmussen, A. Siegbahn, F. Verheugt, J. Weitz (2013)
Parenteral anticoagulants in heart disease: Current status and perspectives (Section II)Thrombosis and Haemostasis, 109
L. Azoulay, S. Dell'aniello, T. Simon, C. Renoux, S. Suissa (2014)
Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes.European heart journal, 35 28
F. Skjøth, T. Larsen, L. Rasmussen, G. Lip (2014)
Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillationThrombosis and Haemostasis, 111
M. Patel, K. Mahaffey, Jyotsna Garg, Guohua Pan, D. Singer, W. Hacke, G. Breithardt, J. Halperin, G. Hankey, J. Piccini, R. Becker, C. Nessel, J. Paolini, S. Berkowitz, K. Fox, R. Califf (2011)
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.The New England journal of medicine, 365 10
Shinya Goto, Masatsugu Hori, Norio Tanahashi, Michael Hanna, Suzuko Oikawa, John Alexander, Aristotle Japan (2012)
Apixaban versus Warfarin in Patients with Atrial FibrillationYearbook of Medicine, 2012
T. Potpara (2015)
Dabigatran in ‘real-world’ clinical practice for stroke prevention in patients with non-valvular atrial fibrillationThrombosis and Haemostasis, 114
G. Lip, K. Haguenoer, C. Saint-Etienne, L. Fauchier (2014)
Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation.Chest, 146 3
T. Larsen, F. Skjøth, P. Nielsen, J. Kjældgaard, G. Lip (2016)
Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort studyThe BMJ, 353
E. Dimitrova, M. Polovina, Stanislav Petranov, Hortensia Djergo, G. Lip, T. Potpara, M. Polovina, S. Milanov, Marija Pavlović, M. Petrovic, S. Simovic, G. Mitić, M. Milanov, J. Savic, S. Gnip, P. Radović, S. Markovic, I. Koncarevic, J. Gavrilovic, T. Aćimović, D. Djikic, Semir Malić, J. Hodzic, M. Stojanović, M. Ilić, M. Zlatar, D. Matic, S. Lazić, V. Perić, S. Markovic, S. Kovačević, A. Arandjelović, M. Ašanin, M. Zdravković, G. Dan, A. Breha, A. Dan, R. Musetescu, M. Popescu, E. Bădilă, C. Georgescu, S. Pop, R. Popescu, S. Neamtu, Floriana Oancea, E. Trendafilova, E. Dimitrova, Evgenii Goshev, Anna Velichkova, Stanislav Petranov, D. Kamenova, Penka Kamenova, Svetoslava Elefterova, V. Shterev, M. Zekova, Stela Diukiandzhieva, B. Dimitrov, T. Sotirov, V. Simeonova, Dimitrina Drianovska, L. Boiadzhieva, D. Buchukova, A. Goda, V. Paparisto, H. Gjergo, A. Mijo, E. Shirka, V. Gjini, U. Ekmekçiu, I. Refatllari, Z. Kusljugic, D. Lončar, D. Mršić, Hazim Tulumović, B. Pojskić, Alma Sijamija, A. Bijedić, Indira Karamujic, I. Bijedić, Sanela Halilović, Š. Sokolović, Š. Manola, I. Zeljković, N. Pavlović, Vjekoslav Radeljić, S. Brusich, A. Anić, M. Jerić, P. Pekić, Kresimir Milas, L. Musić, N. Bulatović, A. Nenezić, D. Asanovic (2016)
Stroke prevention in atrial fibrillation and ‘real world’ adherence to guidelines in the Balkan Region: The BALKAN-AF SurveyScientific Reports, 6
G. Lip, C. Laroche, P. Ioachim, L. Rasmussen, L. Vitali-Serdoz, L. Petrescu, D. Darabantiu, H. Crijns, P. Kirchhof, P. Vardas, L. Tavazzi, A. Maggioni, G. Boriani (2014)
Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry).European heart journal, 35 47
S. Husted, R. Caterina, F. Andreotti, H. Arnesen, F. Bachmann, K. Huber, J. Jespersen, S. Kristensen, G. Lip, J. Morais, L. Rasmussen, A. Siegbahn, R. Storey, J. Weitz (2014)
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novelThrombosis and Haemostasis, 111
W. Lo‐Ciganic, W. Gellad, H. Huskamp, N. Choudhry, C. Chang, Ruoxin Zhang, B. Jones, H. Guclu, Seth Richards-Shubik, J. Donohue (2016)
Who Were the Early Adopters of Dabigatran?: An Application of Group-based Trajectory ModelsMedical Care, 54
Xiaoxi Yao, N. Abraham, L. Sangaralingham, M. Bellolio, R. McBane, Nilay Shah, P. Noseworthy (2016)
Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial FibrillationJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 5
G. Lip, S. Windecker, K. Huber, P. Kirchhof, F. Marín, J. Berg, K. Haeusler, G. Boriani, D. Capodanno, M. Gilard, U. Zeymer, D. Lane, R. Storey, H. Bueno, J. Collet, L. Fauchier, S. Halvorsen, M. Lettino, J. Morais, C. Mueller, T. Potpara, L. Rasmussen, A. Rubboli, J. Tamargo, M. Valgimigli, J. Zamorano (2014)
Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm AssociationEuropean heart journal, 35 45
L. Poller, J. Jespersen, S. Ibrahim (2009)
Dabigatran versus warfarin in patients with atrial fibrillation.The New England journal of medicine, 361 27
R. Caterina, A. Camm (2014)
What is 'valvular' atrial fibrillation? A reappraisal.European heart journal, 35 47
( Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). Eur Heart J. 2016;37:2893–2962.)
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). Eur Heart J. 2016;37:2893–2962.Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). Eur Heart J. 2016;37:2893–2962., Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). Eur Heart J. 2016;37:2893–2962.
(2009)
Dabigatran versus warfarin in patients with atrial fibrillationN Engl J Med, 361
L. Friberg, M. Rosenqvist, G. Lip (2012)
Net Clinical Benefit of Warfarin in Patients With Atrial Fibrillation: A Report From the Swedish Atrial Fibrillation Cohort StudyCirculation, 125
P. Gallego, V. Roldán, F. Marín, J. Gálvez, M. Valdés, V. Vicente, G. Lip (2014)
SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation.The American journal of medicine, 127 11
E. Hylek, C. Evans-Molina, Carol Shea, Lori Henault, S. Regan (2007)
Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial FibrillationCirculation, 115
S. Apostolakis, R. Sullivan, B. Olshansky, G. Lip (2013)
Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score.Chest, 144 5
Chern-En Chiang, T. Chao, E. Choi, Toon Lim, R. Krittayaphong, Mingfang Li, Minglong Chen, Yutao Guo, Ken Okumura, G. Lip (2022)
Stroke Prevention in Atrial FibrillationJACC Asia, 2
Marco Proietti, G. Lip (2015)
Simple decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant: using the SAMe-TT2R2 score.European heart journal. Cardiovascular pharmacotherapy, 1 3
E. Hylek, D. Ko, C. Cove (2014)
Gaps in translation from trials to practice: Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillationThrombosis and Haemostasis, 111
S. Apostolakis, R. Sullivan, B. Olshansky, G. Lip
Factors Affecting Quality of Anticoagulation Control Among Patients With Atrial Fibrillation on Warfarin The SAMe-TT 2 R 2 Score
P. Gallego, V. Roldán, F. Marín, M. Romera, M. Valdés, V. Vicente, G. Lip (2013)
Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillationThrombosis and Haemostasis, 110
Stefan Hohnloser, G. Hindricks, S. Kristensen, Frans Rutten (2012)
2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 14 10
A. Shields, G. Lip (2015)
Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillationJournal of Internal Medicine, 278
G. Lip, A. Keshishian, S. Kamble, Xianying Pan, J. Mardekian, R. Horblyuk, M. Hamilton (2016)
Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarinThrombosis and Haemostasis, 116
T. Potpara, G. Lip (2015)
Patterns in atrial fibrillation management and ‘real-world’ adherence to guidelines in the Balkan Region: an overview of the Balkan–atrial fibrillation survey.European heart journal, 36 30
R. Caterina, S. Husted, L. Wallentin, F. Andreotti, H. Arnesen, F. Bachmann, C. Baigent, K. Huber, J. Jespersen, S. Kristensen, G. Lip, J. Morais, L. Rasmussen, A. Siegbahn, F. Verheugt, J. Weitz (2013)
Vitamin K antagonists in heart disease: Current status and perspectives (Section III)Thrombosis and Haemostasis, 110
A. Banerjee, D. Lane, C. Torp-Pedersen, G. Lip (2011)
Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: A modelling analysis based on a nationwide cohort studyThrombosis and Haemostasis, 107
Adv Ther (2017) 34:2043–2057 DOI 10.1007/s12325-017-0589-5 ORIGINAL RESEARCH The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF Survey . . . . Tatjana S. Potpara Elina Trendafilova Gheorghe-Andrei Dan Artan Goda . . . . . Zumreta Kusljugic Sime Manola Ljilja Music Viktor Gjini Belma Pojskic . . . . Mircea Ioakim Popescu Catalina Arsenescu Georgescu Elena S. Dimitrova Delyana Kamenova . . . . . Uliks Ekmeciu Denis Mrsic Ana Nenezic Sandro Brusich Srdjan Milanov . . Ivan Zeljkovic Gregory Y. H. Lip On behalf of the BALKAN-AF Investigators Received: June 12, 2017 / Published online: August 9, 2017 The Author(s) 2017. This article is an open access publication countries a prospective survey was conducted ABSTRACT between December 2014 and February 2015, and we report results pertinent to the use of Introduction: Data on management of atrial non-vitamin K antagonist oral anticoagulants fibrillation (AF) in the Balkan Region are scarce. (NOACs). To capture the patterns in AF management in Methods: A 14-week prospective, multicenter contemporary clinical practice in the Balkan survey of consecutive AF patients seen by car- diologists or internal medicine specialists
Advances in Therapy – Springer Journals
Published: Aug 9, 2017
Access the full text.
Sign up today, get DeepDyve free for 14 days.